{"id":"gr1501-low-dose","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"However, the exact mechanism of action for GR1501 is not well-documented, and further research is needed to fully understand its effects.","oneSentence":"GR1501 is a low-dose drug that targets a specific molecular pathway.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:13.558Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05881785","phase":"PHASE3","title":"Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2022-06-13","conditions":"Axial Spondyloarthritis","enrollment":465}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GR1501 low dose","genericName":"GR1501 low dose","companyName":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","companyId":"genrix-shanghai-biopharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}